Katarzyna Fijał1, Piotr Popik, Agnieszka Nikiforuk. 1. Department of Behavioral Neuroscience and Drug Development, Institute of Pharmacology, Polish Academy of Sciences, 12 Smętna Street, 31-343, Kraków, Poland.
Abstract
RATIONALE: Some novel antipsychotics manifest antagonistic activity at serotonin-6 receptors; however, little is known about the role of 5-HT6 receptors in ameliorating sensory gating deficits. OBJECTIVE: We evaluated the effects of the combined administration of the 5-HT6 receptor antagonist SB 271046 with clozapine and haloperidol, as well as the co-administration of SB 271046 or SB 399885 with risperidone and the 5-HT2A antagonist M100907, to overcome the deficits induced by MK-801 in the prepulse inhibition (PPI) test. RESULTS: MK-801 (0.1 mg/kg) produced reliable PPI deficits. Administration of SB 271046 (6 and 9 mg/kg), SB 399885 (3 and 6 mg/kg), clozapine (2.5 mg/kg), haloperidol (0.1 and 0.2 mg/kg), risperidone (0.25-1 mg/kg), and M100907 (0.5 and 1 mg/kg) did not affect the MK-801-induced deficits, but the administration of clozapine (5 mg/kg) did reverse the effects of MK-801. In MK-801-treated rats, the co-administration of inactive doses of clozapine (2.5 mg/kg) and SB 271046 (6 mg/kg) reversed the PPI impairments compared to animals that were administered inactive doses of either clozapine or SB 271046 alone. Co-administration of risperidone (1 mg/kg) or M100907 (0.5 mg/kg) with SB 271046 (6 mg/kg) or SB 399885 (3 mg/kg) also attenuated the MK-801-induced PPI deficits. In contrast, joint administration of haloperidol and SB 271046 had no effect on the PPI deficit. CONCLUSION: The present results suggest that the 5-HT6 receptors may play adjunctive roles in antipsychotic drug action, and that the combination of 5-HT2A and 5-HT6 antagonism may represent an important element in the pharmacological profile of antipsychotic drugs.
RATIONALE: Some novel antipsychotics manifest antagonistic activity at serotonin-6 receptors; however, little is known about the role of 5-HT6 receptors in ameliorating sensory gating deficits. OBJECTIVE: We evaluated the effects of the combined administration of the 5-HT6 receptor antagonist SB 271046 with clozapine and haloperidol, as well as the co-administration of SB 271046 or SB 399885 with risperidone and the 5-HT2A antagonist M100907, to overcome the deficits induced by MK-801 in the prepulse inhibition (PPI) test. RESULTS:MK-801 (0.1 mg/kg) produced reliable PPI deficits. Administration of SB 271046 (6 and 9 mg/kg), SB 399885 (3 and 6 mg/kg), clozapine (2.5 mg/kg), haloperidol (0.1 and 0.2 mg/kg), risperidone (0.25-1 mg/kg), and M100907 (0.5 and 1 mg/kg) did not affect the MK-801-induced deficits, but the administration of clozapine (5 mg/kg) did reverse the effects of MK-801. In MK-801-treated rats, the co-administration of inactive doses of clozapine (2.5 mg/kg) and SB 271046 (6 mg/kg) reversed the PPI impairments compared to animals that were administered inactive doses of either clozapine or SB 271046 alone. Co-administration of risperidone (1 mg/kg) or M100907 (0.5 mg/kg) with SB 271046 (6 mg/kg) or SB 399885 (3 mg/kg) also attenuated the MK-801-induced PPI deficits. In contrast, joint administration of haloperidol and SB 271046 had no effect on the PPI deficit. CONCLUSION: The present results suggest that the 5-HT6 receptors may play adjunctive roles in antipsychotic drug action, and that the combination of 5-HT2A and 5-HT6 antagonism may represent an important element in the pharmacological profile of antipsychotic drugs.
Authors: Dan Rujescu; Andreas Bender; Martin Keck; Annette M Hartmann; Frauke Ohl; Hanna Raeder; Ina Giegling; Just Genius; Robert W McCarley; Hans-Jürgen Möller; Heinz Grunze Journal: Biol Psychiatry Date: 2006-01-19 Impact factor: 13.382
Authors: Allison L McIntosh; Theresa M Ballard; Lucinda J Steward; Paula M Moran; Kevin C F Fone Journal: Psychopharmacology (Berl) Date: 2013-02-09 Impact factor: 4.530
Authors: Ignasi Oliveras; Ana Sánchez-González; Daniel Sampedro-Viana; Maria Antonietta Piludu; Cristóbal Río-Alamos; Osvaldo Giorgi; Maria G Corda; Susana Aznar; Javier González-Maeso; Cristina Gerbolés; Gloria Blázquez; Toni Cañete; Adolf Tobeña; Alberto Fernández-Teruel Journal: Psychopharmacology (Berl) Date: 2017-02-02 Impact factor: 4.530
Authors: Paweł Zajdel; Katarzyna Grychowska; Szczepan Mogilski; Rafał Kurczab; Grzegorz Satała; Ryszard Bugno; Tomasz Kos; Joanna Gołębiowska; Natalia Malikowska-Racia; Agnieszka Nikiforuk; Séverine Chaumont-Dubel; Xavier Bantreil; Maciej Pawłowski; Jean Martinez; Gilles Subra; Frédéric Lamaty; Philippe Marin; Andrzej J Bojarski; Piotr Popik Journal: J Med Chem Date: 2021-09-01 Impact factor: 7.446